Is montelukast effective and well tolerated in the management of asthma in young children? Part B: Clinical commentary

Paediatrics and Child Health

Volumn 12, Issue 4, 2007, Pages 309-310

  Smith, Michael B H ^a  

^a Royal Victoria Hospitals Trust   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; CORTICOSTEROID; MONTELUKAST; PLACEBO;

ASTHMA; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; NOTE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 34250223459     PISSN: 12057088     EISSN: None     Source Type: Journal    
DOI: 10.1093/pch/12.4.309     Document Type: Note

References (11)

1. Bisgaard H. Leukotriene modifiers in pediatric asthma management. Pediatr 2001;107:381-90.
2. Bisgaard H, Zielen S, Garcia-Garcia ML, et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Resp Crit Care Med 2005;171:315-22.
3. Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatr 2001;108:E48.
4. van Adelsberg J, Moy J, Wei LX, Tozzi CA, Knorr B, Reiss TF. Safety, tolerability, and exploratory efficacy of montelukast in 6- to 24-month-old patients with asthma. Curr Med Res Opin 2005;21:971-9.
5. Maspero JF, Duenas-Meza E, Volovitz B, et al. Oral montelukast versus inhaled beclomethasone in 6- to 11-year-old children with asthma: Results of an open-label extension study evaluating long-term safety, satisfaction, and adherence with therapy. Curr Med Res Opin 2001;17:96-104.
6. Jones C, Santanello NC, Boccuzzi SJ, Wogen J, Strub P, Nelsen LM. Adherence to prescribed treatment for asthma: Evidence from pharmacy benefits data. J Asthma 2003;40:93-101.
7. Ducharme FM and Di Salvio F. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2004: Art. No: CD002314. DOI: 10.1002/14651858.CD002314.pub2.
8. Becker A, Lemière C, Bérubé D, et al. Summary of recommendations from the Canadian Asthma Consensus Guidelines, 2003. CMAJ 2005;173(Suppl 6):S1-S56.
9. British Thoracic Society; Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax 2003;58(Suppl 1):i1-94.
10. van Adelsberg J, Philip G, Pedinoff AJ, et al; Montelukast Fall Rhinitis Study Group. Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period. Allergy 2003;58:1268-76.
11. Robertson CF, Price D, Henry R et al. Short-course montelukast for intermittent asthma in children: A randomized controlled trial. Am J Respir Crit Care Med 2007;175:323-9.